Expanding the Promise of Immunotherapy

Leveraging elite immune responses to develop novel cancer immunotherapies


The Right People in the Right Place at the Right Time

Making advancements in immuno-oncology through strategic partnerships



September 11, 2018
OncoResponse Raises $40 Million in Series B Financing

January 2, 2018
OncoResponse Expands Scientific Leadership with the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D.. Puri as VP of R&D